FERRING-PHARMACEUTICALS
9.6.2022 13:02:08 CEST | Business Wire | Press release
Ferring Pharmaceuticals today announced it has entered into a strategic collaboration with I-Mab to further develop olamkicept in inflammatory bowel disease (IBD) and related inflammatory conditions.
Olamkicept is the first and only clinical stage selective interleukin-6 inhibitor that works through the trans-signaling mechanism. Interleukin-6 is associated with a number of inflammatory conditions, such as IBD. In 2021, positive results from a Phase 2 study evaluating the efficacy and safety of olamkicept in patients with active ulcerative colitis (UC) were presented at the European Crohn’s and Colitis Organization (ECCO) meeting.
Ferring had previously entered into a license agreement with I-Mab in 2016 that granted I-Mab exclusive rights to develop and commercialize olamkicept in Greater China and South Korea. This new collaboration enables Ferring to invest in the development of olamkicept globally and provides an option for I-Mab to collaborate with Ferring in the future development of olamkicept at a pre-defined development milestone. The financial details of this deal are undisclosed.
“Ferring is committed to developing novel therapies where unmet needs remain for patients living with complex medical conditions, including inflammatory bowel disease," said Araz Raoof, President of Ferring Research Institute and Senior Vice President, Global Drug Discovery & External Innovation at Ferring Pharmaceuticals. “We are excited to expand our collaboration and advance olamkicept globally, as we continue to invest in our specialty area of gastroenterology.”
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs around 6,000 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
Learn more at www.ferring.com , or connect with us on Twitter , Facebook , Instagram , LinkedIn and YouTube .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005091/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCL Group and UpLink Launch Fifth Global Aquapreneur Innovation Challenge to Advance Future Water Systems22.4.2026 13:16:00 CEST | Press release
HCL Group, in partnership with UpLink - the early-stage innovation initiative of the World Economic Forum - has launched the fifth global challenge under the Aquapreneur Innovation Initiative, titled Transforming Water Systems. Applications will be open from 22 April to 4 June 2026. The top 10 winners will receive a total financial award of CHF 1.75 million. For details on eligibility and application criteria, visit: UpLink - Transforming Water Systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421866128/en/ The Aquapreneur Innovation Initiative is a five-year, CHF 15 million collaboration between UpLink, HCL Group, and the World Economic Forum’s Food and Water Initiative, focused on building a global innovation ecosystem for freshwater solutions. Important Dates to Note 22 April to 4 June 2026 Open for submissions July to August 2026 Review and selection process January 2027 Announcement of the winners As water syst
Veristat to Acquire Certara’s Regulatory and Medical Writing Business22.4.2026 13:00:00 CEST | Press release
Strategic acquisition expands and enhances Veristat’s regulatory services to help more clinical trial sponsors develop novel, life-saving therapies across complex disease areas Veristat (the “Company”), a science-first full-service CRO and consultancy that advances complex therapies through the drug development lifecycle to regulatory submission, announced today its intended acquisition of Certara’s Regulatory and Medical Writing business. The team that will join Veristat is known for its white-glove advisory services and deep expertise authoring clinical and non-clinical documents throughout the drug development lifecycle. The acquisition is supported by WindRose Health Investors, LLC, a New York-based healthcare private equity firm, which remains a partner in driving Veristat's growth trajectory and mission. Notably, the acquisition expands Veristat’s regulatory writing and submission capabilities by adding more than 200 industry experts. Combined with the strong track record and mar
BeOne Medicines to Announce First Quarter 2026 Financial Results on May 622.4.2026 12:01:00 CEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capa
Smartstream Research Reveals Five Realities Redefining Buy-Side Reconciliations22.4.2026 10:05:00 CEST | Press release
Key Facts Over 70% of firms still rely primarily on end-of-day reconciliation, while 53% cite timing differences and data mismatches as the leading causes of breaks. 59% of participants identified external data dependencies as the primary risk, while 47% highlighted internal inconsistencies. And 41% struggle with incomplete or insufficiently enriched data. 69% describe their T+1 model as partially adapted and still evolving. Whilst 41% say T+1 has made data quality a critical priority. Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces new findings from its latest industry research report, Smart Reconciliations: The Buy-Side Perspective, highlighting the structural shifts transforming reconciliation, control, and operational confidence across buy-side firms. Based on insights gathered from a roundtable of senior operations leaders across asset management and investment firms, the report identifies five critical re
‘Concrete in Life 2025/26’ Winners Announced – Spectacular Photographs From Around the World22.4.2026 10:00:00 CEST | Press release
Concrete in Life Photo of the Year from the Philippines wins $10,000 top prize Over 20,000 international entries from professional photographers and smartphone amateurs Concrete is the world’s most used substance after water Powerful and striking images from around the world have been chosen as the winners of the Concrete in Life 2025/26 global photography competition, showcasing the essential role concrete plays in daily life, infrastructure, cities, and design. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422352135/en/ OVERALL WINNER: Pillars Across the Sea by Celbert Palaganas, Cebu City, Philippines Run by the Global Cement and Concrete Association (GCCA), the annual competition received more than 20,000 entries from professional and amateur photographers, as well as smartphone users, spanning every continent. The competition highlights how concrete supports modern life while also offering moments of beauty, creativ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom